

APC Human CD30 (TNFRSF8) Protein (C-His)

| | |
|---------------------------|---------------------|
| Catalog Number: | 804703, 804704 |
| Size: | 25 ug, 100 ug |
| Target Name: | TNFRSF8, CD30, Ki-1 |
| Regulatory Status: | RUO |

PRODUCT DETAILS

| | |
|-------------------------------|---|
| Application: | Flow Cytometry |
| Format: | Liquid, APC |
| Expression Host: | CHO |
| Species: | Human |
| Sources: | Recombinant Human CD30 protein (phe19-Lys379) with C-terminus His tag is expressed in CHO cells and conjugated to APC. |
| Accession Number: | P28908 |
| Molecular Weight: | The protein has a predicted molecular weight of 40 kDa. Under DTT-reducing conditions, it migrates at approximately 50-80 kDa on SDS-PAGE prior to conjugation. |
| Affinity Tag: | C-His |
| Formulation: | 1xPBS buffer, pH7.4, 0.09% NaN ₃ with a carrier protein |
| Endotoxin level: | Not tested |
| Protein Concentration: | 25µg size is bottled at 0.1mg/mL concentration. 100 µg size is bottled at lot specific concentration. |
| Storage and Handling: | Briefly centrifuge the vial upon receipt. An unopened vial may be stored at 2-8°C for up to six months. |

BACKGROUND INFORMATION

CD30, also known as TNFRSF8, is a 120 kDa type I transmembrane glycoprotein from the TNF receptor superfamily. It is expressed on activated T, B, and NK cells, but not resting cells. CD30 is cleaved by metalloproteinases into a soluble form and is highly expressed in classical Hodgkin lymphoma and anaplastic large cell lymphoma. It interacts with proteins like TRAF1, TRAF2, and TRAF5, activating NF-κB signaling. This signaling regulates the proliferative potential of autoreactive CD8 T cells and protects against autoimmunity. CD30 is a therapeutic target in lymphoma immunotherapy and plays a role in autoimmune diseases like rheumatoid arthritis.